

June 1, 2021

Listing Department

BSE LIMITED

P J Towers, Dalal Street, Fort,
Mumbai-400 001

Code: 531335

Listing Department

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051

Code: ZYDUSWELL

Sub: Submission of half yearly Disclosure on Consolidated Related Party Transactions.

Ref: Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended March 31, 2021.

This is for your information and records.

Thanking you,

Yours faithfully,

For, **ZYDUS WELLNESS LIMITED**

DHANRAJ P. DAGAR

COMPANY SECRETARY

Encl: As above

Transactions during period October 1, 2020 to March 31, 2021 with related parties – in Table - B						
Value of transaction [₹ - Lakhs]						
Sr. No.	Nature of Transaction	Holding Company	Fellow Subsidiaries	Key Managerial Personnel	Enterprises significantly influenced by Directors and/ or their relatives	Other entities where significant influence exists
1	Purchase of Goods	10	-	-	-	-
2	Purchase of Services	11	-	-	14	-
3	Director sitting fee and commission	-	-	38	-	-
4	Remuneration	-	-	354	-	-
5	Reimbursement of expense	12	-	-	-	-
6	Sale of Goods	9	361	-	-	-
7	Sale of Services	-	67	-	-	-
8	Interest Expense	-	1,889	-	-	-
9	CSR contributions	-	92	-	-	-
10	Contributions during the year (includes Employee's share and contribution)	-	-	-	-	435
11	Repayment of Borrowings	-	60,275	-	-	-
Outstanding as on March 31, 2021						
12	Outstanding Payable	-	50,780	22	-	-
13	Outstanding Receivable	1	-	-	-	-

Transactions during period October 1, 2019 to March 31, 2020 with related parties – in Table - B						
Value of transaction [₹ - Lakhs]						
Sr. No.	Nature of Transaction	Holding Company	Fellow Subsidiaries	Key Managerial Personnel	Enterprises significantly influenced by Directors and/ or their relatives	Other entities where significant influence exists
1	Purchase of Services	10	-	-	10	-
2	Director sitting fee and commission	-	-	19	-	-
3	Remuneration	-	-	225	-	-
4	Reimbursement of expense	94	-	-	-	-
5	Sale of Goods	32	237	-	-	-
6	Sale of Services	-	14	-	-	-
7	Interest Expense	-	11	-	-	-
8	CSR contributions	-	221	-	-	-
9	Dividend Paid	1,833	-	-	-	-
10	Contributions during the year (includes Employee's share and contribution)	-	-	-	-	594
Outstanding as on March 31, 2020						
11	Outstanding Payable	-	280	8	-	-
12	Outstanding Receivable	14	210	-	-	-

Table – B – List of Related Parties:			
A	Name of the Related Parties and Nature of the Related Party Relationship:		
	a	Entity having control over Holding Company : Zydus Family Trust *	
	b	Holding Company: Cadila Healthcare Limited	
	c	Subsidiaries Companies:	
		Liva Investment Limited	
		Liva Nutritions Limited	
		Zydus Wellness Products Limited	
		Zydus Wellness International DMCC	
	d	Fellow Subsidiaries/ Concerns:	
		Zydus Healthcare Limited	Zydus Healthcare (USA) LLC [USA]
		German Remedies Pharmaceuticals Private Limited	Sentynl Therapeutics Inc. [USA]
		Zydus Animal Health and Investments Limited	Zydus Noveltech Inc. [USA]
		Dialforhealth Unity Limited	Hercon Pharmaceuticals LLC [USA]
		Dialforhealth Greencross Limited	Viona Pharmaceuticals Inc. [USA]
		Violio Healthcare Limited	Zydus Therapeutics Inc. [USA]
		Zydus Pharmaceuticals Limited	Zydus Healthcare S.A. (Pty) Ltd [South Africa]
		Biochem Pharmaceutical Private Limited	Simayla Pharmaceuticals (Pty) Ltd [South Africa]
		Zydus Strategic Investments Limited	Script Management Services (Pty) Ltd [South Africa]
		Zydus VTEC Limited	Zydus France, SAS [France]
		Zydus Foundation **	Laboratorios Combix S.L. [Spain]
		M/s. Recon Pharmaceuticals and Investments, a Partnership Firm	Etna Biotech S.R.L. [Italy]
		Alidac Healthcare (Myanmar) Limited [Myanmar]	Zydus Nikkho Farmaceutica Ltda. [Brazil]
		Zydus Healthcare Philippines Inc. [Philippines]	Zydus Pharmaceuticals Mexico SA De CV [Mexico]
		Zydus Lanka (Private) Limited [Sri Lanka]	Zydus Pharmaceuticals Mexico Services Company SA De C.V. [Mexico]
		Zydus International Private Limited [Ireland]	Zydus Worldwide DMCC [Dubai]
		Zydus Netherlands B.V. [the Netherlands]	Zydus Discovery DMCC [Dubai]
		Zydus Pharmaceuticals (USA) Inc. [USA]	Nesher Pharmaceuticals (USA) LLC [USA]
		Zydus Hospira Oncology Private Limited	ZyVet Animal Health Inc. [USA]
		Zydus Takeda Healthcare Private Limited	Bayer Zydus Pharma Private Limited
	e	Key Managerial Personnel:	
		Dr. Sharvil P. Patel	Non -Executive Chairman
		Mr. Ganesh Nayak	Non-Executive Director
		Mr. Kulin S. Lalbhai	Independent Director
		Mr. Savyasachi S. Sengupta	Independent Director
		Mr. Ashish Bhargava	Nominee Director
		Mr. Srivishnu Raju Nandyala	Independent Director
		Ms. Dharmishtaben N. Raval	Independent Director
		Mr. Tarun G. Arora	Chief Executive Officer & Whole Time Director
		Mr. Umesh V. Parikh	Executive Officer [Chief Financial Officer]
		Mr. Dhanraj P. Dagar	Executive Officer [Company Secretary]

f	Enterprises significantly influenced by Directors and/ or their relatives -	
	Mukesh M. Patel & Co.	Enterprises controlled by Key Director of holding Company
g	Post-Employment Benefits Plan-	
	Zydus Wellness Limited Employee Group Gratuity Scheme	Heinz India Private Limited Employee Provident Fund
	Zydus Wellness Sikkim Employee Group Gratuity Scheme	Heinz India Private Limited Gratuity fund
	Heinz India Private Limited Provident Fund	Heinz India Private Limited Pension fund
* Zydus Family Trust is a related party as per Ind AS		
** Zydus Foundation is a Company incorporated under Section 8 of the Companies Act, 2013 and this Company is prohibited to give any right over their profits to its members.		